Dermatological Uses of High-Dose Intravenous Immunoglobulin

Jolles, Stephen; Hughes, Jenny; Whittaker, Sean

doi:10.1001/archderm.134.1.80

Cited by 141 publications

(103 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, these costs have not been discussed in any depth. High-dose intravenous immunoglobin (hdIVIg) has been used to treat a few cases of EB, however its clinical efficacy is unclear as this treatment was not undertaken within a controlled trial setting (107). No other studies were found related to costs and EB.…”

Section: Epidermolysis Bullosamentioning

confidence: 99%

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

2015

View full text Add to dashboard Cite

A c c e p t e d M a n u s c r i p t 2 Highlights  We systematically reviewed the socioeconomic cost literature for 10 rare diseases. Direct and indirect costs incurred by patients, carers and society were searched. 77 studies were included with an unequal distribution of studies over disease types. Level of existing evidence is highest for diseases with available drug treatments. Indirect costs are in most cases of similar or higher magnitude than direct costs. found to range between 1-2 per 100,000 population (PWS, a sub-type of Histiocytosis, and EB) up to 42 per 100,000 population (Scleroderma). Overall, cost evidence on rare diseases appears to be very scarce (a total of 77 studies were identified across all diseases), with CF (n=29) and Haemophilia (n=22) being relatively well studied, compared to the other conditions, where very limited cost of illness information was available. In terms of data availability, total lifetime cost figures were found only across four diseases, and total annual costs (including indirect costs) across five diseases.Overall, data availability was found to correlate with the existence of a pharmaceutical treatment and indirect costs tended to account for a significant proportion of total costs.Although methodological variations prevent any detailed comparison between conditions, most of the rare diseases examined are associated with significant economic burden, both direct and indirect.

show abstract

Section: Epidermolysis Bullosamentioning

confidence: 99%

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

2015

View full text Add to dashboard Cite

show abstract

“…We describe the first case of febrile ulceronecrotic MHD reported in Greece and the first to be successfully treated with a combination regimen of steroids, high-dose IVIG and methotrexate. Despite a lack of comprehension of its precise mode of action, IVIG is gaining increasing support regarding its use in auto-immune and inflammatory dermatoses, its main advantages being efficacy, safety and the avoidance of side-effects of immunosuppressive agents (steroids, chemotherapeutic agents) [5][6][7] . We believe that in addition to high-dose corticosteroids and methotrexate, IVIG represented an invaluable aid in the treatment of our patient, both in matters of safety, as the primary disease was complicated by sepsis and methotrexate could not be initiated in the initial stages, as well as efficacy, judging from the dramatic improvement of the ulcerations upon initiation of IVIG administration.…”

mentioning

confidence: 99%

Intravenous Immunoglobulins: A Valuable Asset in the Treatment of a Case of Septic Febrile Ulceronecrotic Mucha-Habermann Disease

et al. 2007

View full text Add to dashboard Cite

“…Mechanisms like Fc receptor blockade, anti-idiotypic antibodies or modulation of cytokines were supposed to modulate the immune system after the administration of IVIG [6, 14], which might also be important for dermatological autoimmune diseases. Effects of IVIG have been reported for dermatomyositis [15], pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita, toxic epidermal necrolysis, pemphigoid gestationis, erythema multiforme [16], autoimmune chronic urticaria [17]and linear IgA dermatosis [3, 4]. In these cases, IVIG were mostly administered for several months and the authors often reduced the dose of IVIG without recurrence of symptoms during the periods of observation.…”

Section: Discussionmentioning

confidence: 99%

Transient and Partial Effect of High-Dose Intravenous Immunoglobulin in Polyarteritis nodosa

et al. 2001

View full text Add to dashboard Cite

A 57-year-old male patient suffered from polyarteritis nodosa. He presented with articular pain, polyneuropathy, subcutaneous nodules and nodes on the lower legs. After several immunosuppressive agents (methotrexate, mycophenolate mofetil and prednisolone) had proven to be ineffective, 2 g intravenous immunoglobulin (IVIG) per kilogram body weight were administered within 2 days in combination with 10 mg prednisolone per day. Subsequently, 6 cycles of IVIG were applied in increasing intervals from 4 to 6 weeks resulting in a minimum dosage of 0.33 g/kg/week IVIG. The polyarteritis improved within a few days after the first IVIG application. The intensity of polyneuropathy and arthralgia of polyarteritis decreased during the period of IVIG treatment. Finally, a dose reduction of less than 0.25 g/kg/week IVIG resulted in recurring polyarteritis nodosa, which could not be controlled by further administration of IVIG. Therefore, our data indicate that: (1) IVIG is partially effective in cases of polyarteritis nodosa, but the therapeutic effect is only transient; (2) the success of treatment may be correlated with the dose of IVIG per body weight and week; (3) the efficacy/cost ratio of IVIG in polyarteritis nodosa appears to be low.

show abstract

Dermatological Uses of High-Dose Intravenous Immunoglobulin

Cited by 141 publications

References 45 publications

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

Intravenous Immunoglobulins: A Valuable Asset in the Treatment of a Case of Septic Febrile Ulceronecrotic Mucha-Habermann Disease

Transient and Partial Effect of High-Dose Intravenous Immunoglobulin in Polyarteritis nodosa

Contact Info

Product

Resources

About